

Clinical trials of nicoumalone or phenprocoumon

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
nicoumalone or phenprocoumon vs placebo			
ASPECT , 1994 n=1700/1704 follow-up: 37 months	anticoagulant (nicoumalone or phenprocoumon) versus placebo	hospital survivors of myocardial infarction	

More details and results :

- anticoagulant for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q481>

References

ASPECT, 1994:

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994;343:499-503 [[7906757](#)]

2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
nicoumalone or phenprocoumon vs placebo			
ASPECT , 1994 n=1700/1704 follow-up: 37 months	anticoagulant (nicoumalone or phenprocoumon) versus placebo	hospital survivors of myocardial infarction	

More details and results :

- anticoagulant for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q673>

References

ASPECT, 1994:

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. *Lancet* 1994;343:499-503 [[7906757](#)]